Echo Pharmaceuticals Announces Phase 2 Results for Namisol®, Its' Pipeline Product for Oral Administration of Δ9

  Echo Pharmaceuticals Announces Phase 2 Results for Namisol®, Its' Pipeline
 Product for Oral Administration of Δ9-Tetrahydrocannabinol and Appoints The
                                  Sage Group

  PR Newswire

  AMSTERDAM, CAMBRIDGE, England and CLINTON, New Jersey, July 11, 2013

AMSTERDAM, CAMBRIDGE, England and CLINTON, New Jersey, July 11, 2013
/PRNewswire/ --

Echo Pharmaceuticals ("Echo") announces that Namisol ^® has completed
successfully a Phase II trial with 24 patients suffering from spasticity and
pain due to multiple sclerosis (MS). The trial has been conducted by the
Centre for Human Drug Research (CHDR) in the VU University Medical Center
Amsterdam and it was led by Dr. G.J. Groeneveld, Research Director Neurology &
Pain, CHDR. The clinical trial was a double blind, placebo-controlled study of
Namisol ^® to determine safety, tolerability and efficacy in MS patients. The
outcome of this trial showed efficacy and consistent results on both
spasticity and pain.

 (Logo: )

Simultaneously, The Sage Group has been appointed by Echo Pharmaceuticals to
assist the company in its search for a strategic partner for commercialisation
of its lead Namisol ^® program.

Dr. Vanesa Fernandez, CEO of Echo Pharmaceuticals, said "We are very pleased
that The Sage Group has been selected by our Company to assist in the
commercialisation phase of Namisol ^® . The successful Phase 2 trial in MS
patients is a major milestone for Echo and we believe there will be strong
global interest in working with us to take the product to market. The Sage
Group are very experienced in developing such partnerships and will add a
valuable business development activity to our drug development capability."

Dr. Bill Mason and Wayne Pambianchi of The Sage Group based in Europe and the
USA said "We are delighted to be selected as managers for this exciting
program and we look forward to working with Echo and key interested parties in
the pharma industry to develop strong partnerships for global
commercialisation of Namisol ^® ."

About Namisol ^® Namisol ^® is the world's first oral tablet that contains
pure (≥98,0%), natural Δ9-tetrahydrocannabinol (THC or dronabinol) in fixed
dosages with high, predictable bioavailability (due to Echo's innovative drug
delivery technology Alitra ^TM ) and a long, stable shelf life at room
temperature. Namisol®'s current clinical program includes, in addition to the
MS indication, a number of phase II clinical trials for the indications
behavioral disturbances in patients with Alzheimer's Disease , and Chronic
Pain .

About Echo Pharmaceuticals B.V. ( " Echo " ) Echo Pharmaceuticals is a
privately owned, specialized pharmaceutical company based in The Netherlands,
founded in 2006. Their mission is to develop effective medicines, with a focus
on cannabinoid-based compounds, and drug delivery technologies that contribute
to better the quality of life for a wide range of patients. In 2009, Echo
established their headquarters and clinical research center in Nijmegen, which
is situated in an area of the Netherlands well-known for its ideal environment
for businesses in life sciences and health.

Over the years, Echo has developed outstanding proprietary knowledge and
extensive expertise in the field of isolation, formulation and clinical
development that have led to successful drug- and delivery technology
development programs. Echo Pharmaceuticals has a cGMP certified production and
pharmaceutical development center in Weesp, The Netherlands

About The Sage Group ,  Inc. The Sage Group Inc. is a leader in the provision
of strategic and transactional advice to health care companies in the
pharmaceutical, diagnostics, medical device, biotechnology and life science
fields. Sage currently maintains offices in USA, Europe, Israel, Australia and
Japan. Since its founding in 1994, The Sage Group has served more than 200
clients in the US, Europe and Asia, and completed numerous transactions
including divestitures, alliances, acquisitions and financings with values
ranging from $5 million to $500 million.

The Sage Group is an organization of experienced and successful executives who
are committed to the service of the very vital and dynamic health care
industry and its investors.

Contact Details

Sage Europe: Dr. W. T. Mason Director, Sage Healthcare Email: Tel: +44-(0)1638-508779 Sage  USA : Wayne Pambianchi
Director, Sage Healthcare Email: Tel:

Echo Pharmaceuticals  Netherlands : Dr. Vanesa Fernandez CEO, Echo Pharma
Email: Tel: +31-(0)294-457353
Press spacebar to pause and continue. Press esc to stop.